Alternatives to Ibalizumab If You Can't Fill Your Prescription

Why Ibalizumab Alternatives Matter

Ibalizumab (Trogarzo) is a critical option for people with multidrug-resistant HIV-1 (MDR HIV-1), but access barriers—including insurance denials, infusion center availability, and high cost—can prevent some patients from getting it. If you cannot access ibalizumab, it is essential to know that other FDA-approved options exist for this challenging patient population.

This guide reviews the main alternatives and compares their key features—but every decision must be made with an HIV specialist based on your specific resistance profile, drug history, and clinical situation. Do not switch or stop HIV medications without your doctor's guidance.

The Three Main Drugs for Heavily Treatment-Experienced MDR HIV Patients

Since 2018, the FDA has approved three novel antiretrovirals specifically for heavily treatment-experienced (HTE) adults with MDR HIV-1:

Ibalizumab (Trogarzo) — CD4-directed post-attachment HIV-1 inhibitor; IV infusion every 2 weeks (approved 2018)

Fostemsavir (Rukobia) — HIV attachment inhibitor; oral tablet twice daily (approved 2020)

Lenacapavir (Sunlenca) — HIV capsid inhibitor; subcutaneous injection every 6 months (approved December 2022)

Fostemsavir (Rukobia): The Oral Alternative

Fostemsavir (brand name Rukobia) is an HIV attachment inhibitor that works by a completely different mechanism from ibalizumab. While ibalizumab blocks the virus after it attaches to the CD4 receptor, fostemsavir's active form (temsavir) binds directly to the HIV-1 gp120 envelope protein to prevent the virus from attaching to CD4 cells in the first place.

Key advantages over ibalizumab:

Oral tablet (600 mg twice daily)—no infusions needed

Can be filled at a specialty pharmacy and taken at home

Has shown sustained efficacy through 240 weeks in clinical studies

Considerations:

Has drug interactions—particularly with CYP3A inducers (rifampin, carbamazepine, St. John's Wort)

Also requires prior authorization and specialty pharmacy dispensing

Lenacapavir (Sunlenca): The Long-Acting Injectable

Lenacapavir (brand name Sunlenca) is a first-in-class HIV capsid inhibitor approved in December 2022. It works at multiple stages of the HIV life cycle by interfering with the viral capsid—distinct from all other approved antiretroviral classes.

Key advantages:

Subcutaneous injection given only every 6 months—the longest-acting antiretroviral approved to date

Cost-utility studies suggest it may be more cost-effective than both ibalizumab and fostemsavir over a patient's lifetime

Ibalizumab and lenacapavir can even be used together in some heavily treatment-experienced patients with very limited options

Considerations:

Requires initial 26-week oral lead-in for treatment-naive or certain treatment-experienced patients

Injection site reactions are possible

Older Entry Inhibitors: Maraviroc and Enfuvirtide

Two older entry inhibitors are sometimes used in salvage regimens, though they are less commonly relied upon in 2026:

Maraviroc (Selzentry): A CCR5 antagonist (oral, twice daily) that only works if your HIV strain is CCR5-tropic—requires a tropism test before prescribing.

Enfuvirtide (Fuzeon): A fusion inhibitor requiring twice-daily subcutaneous injections. Rarely used now due to injection burden and the availability of newer options.

Which Alternative Is Right for You?

There is no single right answer. Your HIV specialist will base the decision on:

Your HIV resistance test results (genotypic and phenotypic)

Your history with prior antiretroviral regimens

Your preference for oral vs. injectable medication

Insurance coverage and access logistics

Concomitant medications and potential drug interactions

If you are struggling to access ibalizumab or any HIV medication, medfinder can call pharmacies and providers near you to find which ones can fill your prescription—saving you time and helping you get back on treatment faster.

Want to learn more about ibalizumab itself? See our overview: What Is Ibalizumab? Uses, Dosage, and What You Need to Know.